⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6641595 | 0.77 | — | — | |
| SCHEMBL10583486 | 0.75 | LMNA (0.36) | — | |
| SCHEMBL1903527 | 0.72 | — | — | |
| SCHEMBL8073096 | 0.70 | LMNA (0.36) | — | |
| Glycerin SCHEMBL27397797 | 0.70 | LMNA (0.69) | — | |
| Glycerin SCHEMBL11723709 | 0.70 | LMNA (0.69) | — | |
| SCHEMBL4868603 | 0.69 | — | — | |
| SCHEMBL337338 | 0.69 | — | — | |
| SCHEMBL1868586 | 0.69 | — | — | |
| SCHEMBL2232621 | 0.67 | LMNA (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140860-B1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-09-22 | — | — | EP | claimed |
| US-6593326-B1 | Useful as anti-cancer agents; and processes for their manufacture and pharmaceutical compositions containing them are described. Apoptotic effect in a warm-blooded animal such as man. | ASTRAZENECA AB (SE) | 2003-07-15 | — | — | US | claimed |
| EP-1140860-A1 | PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2001-10-10 | — | — | EP | claimed |
| WO-2000039101-A1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-07-06 | — | — | WO | claimed |
| EP-1140860-B1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| US-6593326-B1 | Useful as anti-cancer agents; and processes for their manufacture and pharmaceutical compositions containing them are described. Apoptotic effect in a warm-blooded animal such as man. | ASTRAZENECA AB (SE) | 2003-07-15 | — | — | US | disclosed |
| EP-1140860-A1 | PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039101-A1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-07-06 | — | — | WO | disclosed |